IL202292A0 - Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment - Google Patents
Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatmentInfo
- Publication number
- IL202292A0 IL202292A0 IL202292A IL20229209A IL202292A0 IL 202292 A0 IL202292 A0 IL 202292A0 IL 202292 A IL202292 A IL 202292A IL 20229209 A IL20229209 A IL 20229209A IL 202292 A0 IL202292 A0 IL 202292A0
- Authority
- IL
- Israel
- Prior art keywords
- chr
- prognosis
- markers
- diagnosis
- treatment
- Prior art date
Links
- 206010006187 Breast cancer Diseases 0.000 title 1
- 208000026310 Breast neoplasm Diseases 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 238000004393 prognosis Methods 0.000 title 1
- 238000012502 risk assessment Methods 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Evolutionary Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Medical Informatics (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IS8647 | 2007-05-25 | ||
| IS8700 | 2007-12-21 | ||
| PCT/IS2008/000012 WO2008146309A2 (en) | 2007-05-25 | 2008-05-21 | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL202292A0 true IL202292A0 (en) | 2010-06-16 |
Family
ID=39661451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL202292A IL202292A0 (en) | 2007-05-25 | 2009-11-23 | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US8580501B2 (enExample) |
| EP (2) | EP2535425A1 (enExample) |
| JP (1) | JP2010527603A (enExample) |
| KR (1) | KR20100017865A (enExample) |
| CN (1) | CN101772578A (enExample) |
| AU (1) | AU2008256219B2 (enExample) |
| CA (1) | CA2688312A1 (enExample) |
| EA (1) | EA018444B1 (enExample) |
| IL (1) | IL202292A0 (enExample) |
| MX (1) | MX2009012722A (enExample) |
| NZ (1) | NZ581858A (enExample) |
| WO (1) | WO2008146309A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2463388B1 (en) | 2005-11-29 | 2017-11-22 | Cambridge Enterprise Limited | Markers for breast cancer |
| CN101772578A (zh) * | 2007-05-25 | 2010-07-07 | 解码遗传学私营有限责任公司 | 作为标记物用在乳腺癌风险评估、诊断、预后和治疗中的在CHR 5p12和10q26上的遗传变异体 |
| CN102144036B (zh) | 2008-07-07 | 2014-07-16 | 解码遗传学私营有限责任公司 | 用于乳腺癌风险评估的遗传变型 |
| GB2466025A (en) * | 2008-12-08 | 2010-06-09 | Univ Francois Rabelais De Tour | C3/ITGAM polymorphisms and cancer prognosis |
| EP2438193B1 (en) * | 2009-06-01 | 2015-07-22 | Genetic Technologies Limited | Methods for breast cancer risk assessment |
| WO2011006214A1 (en) * | 2009-07-16 | 2011-01-20 | Peter Maccallum Cancer Institute | Method of detecting radiation exposure and adverse toxicity thereto |
| US20110151457A1 (en) * | 2009-12-22 | 2011-06-23 | Elitech Holding B.V. | Hypertheromostable endonuclease iv substrate probe |
| WO2011095999A1 (en) * | 2010-02-05 | 2011-08-11 | Decode Genetics Ehf | Genetic variants for predicting risk of breast cancer |
| JP6420543B2 (ja) * | 2011-01-19 | 2018-11-07 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | ゲノムデータ処理方法 |
| US20140329719A1 (en) * | 2011-06-16 | 2014-11-06 | Illumina, Inc. | Genetic variants for predicting risk of breast cancer |
| US11261494B2 (en) | 2012-06-21 | 2022-03-01 | The Chinese University Of Hong Kong | Method of measuring a fractional concentration of tumor DNA |
| WO2014160876A2 (en) * | 2013-03-27 | 2014-10-02 | Memorial Sloan-Kettering Cancer Center | Brca2-specific modifier locus related to breast cancer risk |
| KR101748867B1 (ko) * | 2013-04-19 | 2017-06-20 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 자동화 시스템 |
| WO2015035415A1 (en) | 2013-09-09 | 2015-03-12 | Nantomics, Llc | Method of detecting suceptibility to breast cancer through mutations in the fgfr3 and tp53 genes |
| CN103966310A (zh) * | 2014-01-27 | 2014-08-06 | 广州市体育科学研究所 | 乳腺癌易感基因快速检测试剂盒及检测方法 |
| CN104232774A (zh) * | 2014-09-17 | 2014-12-24 | 湖北维达健基因技术有限公司 | 用于检测乳腺癌易感基因snp的引物、荧光探针及应用 |
| EP3201360A4 (en) | 2014-09-30 | 2018-05-09 | Genetic Technologies Limited | Methods for assessing risk of developing breast cancer |
| CN107250356A (zh) * | 2014-12-16 | 2017-10-13 | 加文医学研究所 | 测序对照 |
| ES2908347T3 (es) | 2015-02-10 | 2022-04-28 | Univ Hong Kong Chinese | Detección de mutaciones para cribado de cáncer y análisis fetal |
| CN106295241A (zh) * | 2015-06-25 | 2017-01-04 | 杭州圣庭生物技术有限公司 | 基于brca1和brca2突变的乳腺癌患病风险评估算法 |
| EP4279612B1 (en) | 2015-07-23 | 2025-07-02 | The Chinese University of Hong Kong | Analysis of fragmentation patterns of cell-free dna |
| CN105586427B (zh) * | 2016-03-10 | 2020-06-19 | 厦门艾德生物医药科技股份有限公司 | 检测人类brca1和brca2基因突变的引物、试剂盒及方法 |
| CN107723350A (zh) * | 2016-08-12 | 2018-02-23 | 嘉兴允英医学检验有限公司 | 一种遗传性乳腺癌突变基因高通量筛查方法 |
| AU2018212272B2 (en) | 2017-01-25 | 2022-04-28 | Grail, Inc. | Diagnostic applications using nucleic acid fragments |
| CN111051536A (zh) | 2017-07-26 | 2020-04-21 | 香港中文大学 | 利用不含细胞的病毒核酸改善癌症筛选 |
| CN107254545B (zh) * | 2017-08-16 | 2020-09-15 | 复旦大学附属华山医院北院 | 一种与乳腺癌化疗毒性相关的snp标志物及其应用 |
| CN107254546B (zh) * | 2017-08-16 | 2020-11-03 | 复旦大学附属华山医院 | 一种与乳腺癌新辅助化疗疗效相关的snp标志物及其应用 |
| CN107729241B (zh) * | 2017-10-12 | 2020-11-03 | 中国矿业大学 | 一种基于变异体分组的软件变异测试数据进化生成方法 |
| KR101985864B1 (ko) * | 2017-12-28 | 2019-06-05 | 주식회사 엔젠바이오 | 유방암 및 난소암 등 암 진단용 조성물 및 이의 용도 |
| CN109913550A (zh) * | 2019-03-21 | 2019-06-21 | 吉林省银丰生物工程技术有限公司 | 乳腺癌新辅助化疗效果预测基因试剂盒 |
| RU2702755C1 (ru) * | 2019-06-24 | 2019-10-11 | Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) | Способ молекулярно-генетической диагностики наследственных форм рака молочной железы |
| CN110358834B (zh) * | 2019-07-12 | 2023-05-16 | 深圳大学 | 一种lncRNA的应用以及试剂盒和药物 |
| CN112837749B (zh) * | 2021-02-01 | 2021-11-26 | 北京百奥纳芯生物科技有限公司 | 一种癌症筛查用基因芯片探针的优选方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| GB8810400D0 (en) | 1988-05-03 | 1988-06-08 | Southern E | Analysing polynucleotide sequences |
| US6054270A (en) | 1988-05-03 | 2000-04-25 | Oxford Gene Technology Limited | Analying polynucleotide sequences |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5744101A (en) | 1989-06-07 | 1998-04-28 | Affymax Technologies N.V. | Photolabile nucleoside protecting groups |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5288644A (en) | 1990-04-04 | 1994-02-22 | The Rockefeller University | Instrument and method for the sequencing of genome |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ES2139598T3 (es) | 1990-07-10 | 2000-02-16 | Medical Res Council | Procedimientos para la produccion de miembros de parejas de union especifica. |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| ES2155822T3 (es) | 1990-12-06 | 2001-06-01 | Affymetrix Inc | Compuestos y su utilizacion en una estrategia de sintesis binaria. |
| EP1279731B1 (en) | 1991-03-01 | 2007-05-30 | Dyax Corporation | Process for the development of binding mini-proteins |
| DE69233367T2 (de) | 1991-04-10 | 2005-05-25 | The Scripps Research Institute, La Jolla | Bibliotheken heterodimerer rezeptoren mittels phagemiden |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| EP0655090B1 (en) | 1992-04-27 | 2000-12-27 | The Trustees Of Dartmouth College | Detection of gene sequences in biological fluids |
| DE69527585T2 (de) | 1994-06-08 | 2003-04-03 | Affymetrix, Inc. | Verfahren und Vorrichtung zum Verpacken von Chips |
| US6287850B1 (en) | 1995-06-07 | 2001-09-11 | Affymetrix, Inc. | Bioarray chip reaction apparatus and its manufacture |
| US6300063B1 (en) | 1995-11-29 | 2001-10-09 | Affymetrix, Inc. | Polymorphism detection |
| WO1997045559A1 (en) | 1996-05-29 | 1997-12-04 | Cornell Research Foundation, Inc. | Detection of nucleic acid sequence differences using coupled ligase detection and polymerase chain reactions |
| US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
| IL163645A0 (en) * | 2002-02-21 | 2005-12-18 | Idgene Pharmaceuticals Ltd | Association of snps in the comt locus and neighboring loci with schizophrenia, bipolar disorder, breast cancer and colorectal cancer |
| AU2003276973A1 (en) * | 2002-09-25 | 2004-04-19 | Amersham Biosciences (Sv) Corp. | Detection methods |
| CA2505786C (en) * | 2002-11-25 | 2011-06-21 | Sequenom, Inc. | Methods for identifying risk of breast cancer and treatments thereof |
| KR101138862B1 (ko) * | 2005-02-14 | 2012-05-14 | 삼성전자주식회사 | 단일염기 다형을 포함하는 유방암과 관련된 폴리뉴클레오티드, 그를 포함하는 마이크로어레이 및 진단 키트 및 그를이용한 유방암 진단 방법 |
| KR101206028B1 (ko) * | 2005-03-05 | 2012-11-28 | 삼성전자주식회사 | 유방암 특이적 다형성 서열을 이용한 유방암의 진단방법,유방암 특이적인 폴리뉴클레오티드 및 상기 폴리뉴클레오티드가 고정되어 있는 마이크로어레이 |
| US7858303B2 (en) * | 2005-03-14 | 2010-12-28 | Wisconsin Alumni Research Foundation | Method of analyzing breast cancer susceptibility and resistance |
| MX2007014447A (es) * | 2005-05-18 | 2008-04-16 | Decode Genetics Ehf | Variantes en cromosoma 8q24.21 que confieren riesgo de cancer. |
| US20070092900A1 (en) * | 2005-10-26 | 2007-04-26 | Stacey Simon N | Methods for diagnosing and characterizing breast cancer and susceptibility to breast cancer |
| CN101772578A (zh) * | 2007-05-25 | 2010-07-07 | 解码遗传学私营有限责任公司 | 作为标记物用在乳腺癌风险评估、诊断、预后和治疗中的在CHR 5p12和10q26上的遗传变异体 |
-
2008
- 2008-05-21 CN CN200880100074A patent/CN101772578A/zh active Pending
- 2008-05-21 EA EA200971079A patent/EA018444B1/ru not_active IP Right Cessation
- 2008-05-21 MX MX2009012722A patent/MX2009012722A/es active IP Right Grant
- 2008-05-21 CA CA002688312A patent/CA2688312A1/en not_active Abandoned
- 2008-05-21 WO PCT/IS2008/000012 patent/WO2008146309A2/en not_active Ceased
- 2008-05-21 US US12/303,238 patent/US8580501B2/en not_active Expired - Fee Related
- 2008-05-21 JP JP2010508970A patent/JP2010527603A/ja active Pending
- 2008-05-21 KR KR1020097026476A patent/KR20100017865A/ko not_active Ceased
- 2008-05-21 EP EP12163654A patent/EP2535425A1/en not_active Withdrawn
- 2008-05-21 EP EP08763758A patent/EP2164984A2/en not_active Withdrawn
- 2008-05-21 AU AU2008256219A patent/AU2008256219B2/en not_active Ceased
- 2008-05-21 NZ NZ581858A patent/NZ581858A/en not_active IP Right Cessation
-
2009
- 2009-11-23 IL IL202292A patent/IL202292A0/en unknown
-
2013
- 2013-10-09 US US14/050,052 patent/US20140179546A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US8580501B2 (en) | 2013-11-12 |
| KR20100017865A (ko) | 2010-02-16 |
| AU2008256219B2 (en) | 2014-06-05 |
| JP2010527603A (ja) | 2010-08-19 |
| AU2008256219A1 (en) | 2008-12-04 |
| EP2164984A2 (en) | 2010-03-24 |
| WO2008146309A2 (en) | 2008-12-04 |
| CA2688312A1 (en) | 2008-12-04 |
| EA018444B1 (ru) | 2013-08-30 |
| EP2535425A1 (en) | 2012-12-19 |
| CN101772578A (zh) | 2010-07-07 |
| US20110015081A1 (en) | 2011-01-20 |
| EA200971079A1 (ru) | 2010-06-30 |
| WO2008146309A3 (en) | 2009-01-22 |
| US20140179546A1 (en) | 2014-06-26 |
| MX2009012722A (es) | 2009-12-11 |
| NZ581858A (en) | 2012-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL202292A0 (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| IL201217A0 (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| IL210439A0 (en) | Genetic variants as markers for use in urinary bladder cancer risk assessment, diagnosis, prognosis and treatment | |
| IL202674A0 (en) | Genetic variants on chr 15q24 as markers for use in diagnosis, prognosis and treatment of exfoliation syndrome and glaucoma | |
| EP2179037A4 (en) | DIAGNOSIS, FORECASTING AND TREATMENT PROCEDURES | |
| PL2387395T3 (pl) | Inhibitory Axl do zastosowania w terapii skojarzonej do zapobiegania, leczenia lub postępowania z nowotworem przerzutowym | |
| EP2046973A4 (en) | METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY | |
| IL242168A0 (en) | Activin actriia antagonists and uses for the treatment or prevention of breast cancer | |
| EP2115161A4 (en) | GENETIC METHYLATION IN THE DIAGNOSIS OF CANCERS | |
| IL206748A (en) | Molecular test for @cancer @ breast cancer @ | |
| ZA201108562B (en) | A system,method,and luminescent marker for improved diffuse luminescent imaging or tomography in scattering media | |
| IL210504A0 (en) | Genetic variants for breast cancer risk assessment | |
| IL217120A0 (en) | Single nucleotide polymorphisms in brca1 and diagnostic methods of assessing cancer risk based on the same | |
| IL213410A0 (en) | Methods and compositions for diagnostic use in cancer patients | |
| ZA201002808B (en) | Methods and compositions for diagnostic use in cancer patients | |
| IL204584A0 (en) | Compounds for use in imaging, diagnosing, and/or treatment of diseases of the central nervous system or of tumors | |
| EP2148675A4 (en) | ANTI-CANCER FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
| SI1766056T1 (sl) | Oligonukleotidi za diagnozo raka na prsih | |
| HUE031337T2 (hu) | Opioidok rezisztens rákos betegek kezelésében történõ alkalmazásra | |
| EP2198041A4 (en) | METHOD AND COMPOSITION FOR CANCER DIAGNOSIS AND TREATMENT | |
| WO2009089102A3 (en) | Identification and characterization of pregnancy- associated genetic signatures and use thereof for diagnosis and treatment of breast cancer | |
| ZA200908630B (en) | Genetic variants on CHR 5PL2 and 10Q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| HK1142369A (en) | Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment | |
| PL2220256T3 (pl) | Sposób diagnozowania in vitro raka skóry | |
| HK1140232A (en) | Genetic variants on chr2 and chr16 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment |